← Leaderboards
Diane W. Wara
University Of California San Francisco
$7,985,315
Attributed
$7,985,315
Total exposure
36
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2005–06$2.5M$1.9M$1.3M$625K$0
'05
'06
Funding mix
By agency
NIH$7,985,315 · 36
By mechanism
U01$5,478,316 · 1
M01$2,506,999 · 35
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Karen P. Beckerman$564
- Alejandro Dorenbaum$25,799
- Ann Petru$791,951
- Joseph A. Kitterman$1,599,423
- Judith T. Moskowitz$25,368,406
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationPediatric AidsAids TherapyChild (0-11)Hiv InfectionsClinical Trial Phase ICombination ChemotherapyDrug Screening /EvaluationAntiaids AgentPharmacokineticsHuman Pregnant SubjectAids Education /PreventionVertical TransmissionAdolescence (12-20)ImmunotherapyHuman Immunodeficiency Virus 1Patient Oriented ResearchClinical TrialsNevirapineInfant Human (0-1 Year)AtovaquonePathologic Process
Grant awards (122)
Northern California Pediatrics AIDS Treatment Center$312,816
U01 · FY2006 · AI · contact PI
Northern California Pediatrics AIDS Treatment Center$869,956
U01 · FY2005 · AI
PEDIATRIC LATE OUTCOMES PROTOCOL (AIDS CLINICAL TRIALS GROUP: 219C)$481,196
M01 · FY2005 · RR
CLINICAL AND MOLECULAR INVESTIGATION OF PRIMARY IMMUNODEFICIENCIES$282,560
M01 · FY2005 · RR
DEFECTIVE T- AND B- CELL SIGNALING IN PATIENTS WITH INHERITED IMMUNODEFICIENCIES$132,106
M01 · FY2005 · RR
PACTG 1020-A, VERSION 20$120,645
M01 · FY2005 · RR
PACTG P1025: PERINATAL CORE PROTOCOL FOR DATA FROM HIV-INFECTED PREGNANT WOMEN$67,948
M01 · FY2005 · RR
PACTG P1057: PHASE I/II RANDOMIZED TRIAL OF COLD ADAPTED INFLUENZA VACCINE$15,255
M01 · FY2005 · RR
PACTG P1030: PHASE I/II STUDY OF LOPINAVIR/RITONAVIR IN HIV-1 INFECTED INFANTS$12,481
M01 · FY2005 · RR
PACTG P1045: MORPHOLOGIC AND METABOLIC ABNORMALITIES IN CHILDREN &YOUTH$8,320
M01 · FY2005 · RR
EFFECTS OF HAART ON THE RECOVERY OF IMMUNE FUNCTION IN HIV-INFECTED CHILDREN$8,320
M01 · FY2005 · RR
PACTG P1026S:PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS DURING PREGNANCY$4,160
M01 · FY2005 · RR
PACTG P1024: EVALUATION OF PNEUMOCOCCAL VACCINE IN HIV-INFECTED CHILDREN$2,775
M01 · FY2005 · RR
PACTG P1042S: COGNITIVE, BEHAVIORAL AND PSYCHOSOCIAL CORRELATES$2,775
M01 · FY2005 · RR
PHASE I/II STUDY OF ALVAC HIV VACCINE IN CHILDREN$2,772
M01 · FY2005 · RR
Northern California Pediatrics AIDS Treatment Center$328,983
U01 · FY2004 · AI
Pediatric late outcomes protocol (ACTG 219C)$280,262
M01 · FY2004 · RR
CLINICAL AND MOLECULAR INVESTIGATION OF PRIMARY IMMUNODEFICIENCIES$229,291
M01 · FY2004 · RR
Phase I/II trial of subcutaneous IL-2 with antiretroviral therapy in HIV$146,551
M01 · FY2004 · RR
Defective T- and B- cell signaling in patients with inherited immunodeficiencies$125,753
M01 · FY2004 · RR
PACTG P1030: Phase I/II study of lopinavir/ritonavir in HIV-1 infected infants$97,342
M01 · FY2004 · RR
PACTG P1025: Perinatal core protocol for data from HIV-infected pregnant women$95,205
M01 · FY2004 · RR
PACTG 1020-A, Version 2.0$22,464
M01 · FY2004 · RR
PACTG P1021: Emtricitabine with efavirenz and Didanosine in a once daily regimen$7,487
M01 · FY2004 · RR
Phase I/II study of ALVAC HIV vaccine in children$5,350
M01 · FY2004 · RR
PACTG P1024: Evaluation of pneumococcal vaccine in HIV-infected children$4,278
M01 · FY2004 · RR
PACTG P1026S:PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS DURING PREGNANCY$4,278
M01 · FY2004 · RR
Immunological and neurodevelopmental consequences of chromosome 22q11.2 deletion$1,586
M01 · FY2004 · RR
Northern California Pediatrics AIDS Treatment Center$865,312
U01 · FY2003 · AI
Northern California Pediatrics AIDS Treatment Center$847,590
U01 · FY2002 · AI
PHASE II ROLLING ARM MASTER PROTOCOL OF NOVEL ANTIRETROVIRAL THERAPY IN HIV$0
M01 · FY2002 · RR
PHASE I/II TRIAL OF RECOMBINANT IL 2 IN SYMPTOMATIC HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
IMPACT OF DIAGNOSTIC DISCLOSURE ON HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
PHASE I EVALUATION OF SAFETY/TOXICITY OF ZDV AND DDI COMBINATION THERAPY$0
M01 · FY2002 · RR
PEDIATRIC HIV LATE OUTCOMES PROTOCOL$0
M01 · FY2002 · RR
ATOVAQUONE AND AZT VERSUS TMP IN HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
TREATING SCID DUE TO ADA DEFICIENCY WITH CD34+ SELECTED AUTOLOGOUS STEM CELLS$0
M01 · FY2002 · RR
ATOVAQUONE IN HIV INFECTED INFANTS AND CHILDREN$0
M01 · FY2002 · RR
CLINICAL INVESTIGATION OF THE PATIENT WITH PRIMARY IMMUNODEFICIENCY DISORDER$0
M01 · FY2002 · RR
ACTG 316: NEVIRAPINE VS PLACEBO FOR PREVENTING MATERNAL FETAL TRANSMISSION$0
M01 · FY2002 · RR
ACTG 316: NEVIRAPINE VS PLACEBO FOR PREVENTING MATERNAL FETAL TRANSMISSION$0
M01 · FY2002 · RR
ACTG 395: INDINAVIR W/ STAVUDINE &LAMIVUDINE FOR PEDIATRIC HIV 1 INF$0
M01 · FY2002 · RR
ACTG 366: ANTIRETROVIRAL ALGORITHM FOR CHILDREN OF 4 DRUG COMBINATION$0
M01 · FY2002 · RR
ACTG 377: PRAM 2 COMPARING 4 ANTIRETROVIRAL REGIMENS$0
M01 · FY2002 · RR
QUANTIFYING HIV 1 RNA IN CSF &BLOOD OF HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
ACTG 351: CD4 IGG2 IN HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
NEVIRAPINE VS PLACEBO TO PREVENT MATERNAL-FETAL HIV TRANSMISSION$0
M01 · FY2002 · RR
NORTHERN CALIFORNIA PEDIATRIC AIDS TREATMENT CENTER$1,149,037
U01 · FY2001 · AI
TREATING SCID DUE TO ADA DEFICIENCY WITH CD34+ SELECTED AUTOLOGOUS STEM CELLS$0
M01 · FY2001 · RR
ACTG 316: NEVIRAPINE VS PLACEBO FOR PREVENTING MATERNAL FETAL TRANSMISSION$0
M01 · FY2001 · RR
CLINICAL INVESTIGATION OF THE PATIENT WITH PRIMARY IMMUNODEFICIENCY DISORDER$0
M01 · FY2001 · RR
ATOVAQUONE IN HIV INFECTED INFANTS AND CHILDREN$0
M01 · FY2001 · RR
ATOVAQUONE AND AZT VERSUS TMP IN HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
PEDIATRIC HIV LATE OUTCOMES PROTOCOL$0
M01 · FY2001 · RR
PHASE I EVALUATION OF SAFETY/TOXICITY OF ZDV AND DDI COMBINATION THERAPY$0
M01 · FY2001 · RR
IMPACT OF DIAGNOSTIC DISCLOSURE ON HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
PHASE I/II TRIAL OF RECOMBINANT IL 2 IN SYMPTOMATIC HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
PHASE II ROLLING ARM MASTER PROTOCOL OF NOVEL ANTIRETROVIRAL THERAPY IN HIV$0
M01 · FY2001 · RR
NEVIRAPINE VS PLACEBO TO PREVENT MATERNAL-FETAL HIV TRANSMISSION$0
M01 · FY2001 · RR
ACTG 351: CD4 IGG2 IN HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
QUANTIFYING HIV 1 RNA IN CSF &BLOOD OF HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
ACTG 377: PRAM 2 COMPARING 4 ANTIRETROVIRAL REGIMENS$0
M01 · FY2001 · RR
ACTG 366: ANTIRETROVIRAL ALGORITHM FOR CHILDREN OF 4 DRUG COMBINATION$0
M01 · FY2001 · RR
ACTG 395: INDINAVIR W/ STAVUDINE &LAMIVUDINE FOR PEDIATRIC HIV 1 INF$0
M01 · FY2001 · RR
NORTHERN CALIFORNIA PEDIATRIC AIDS TREATMENT CENTER$1,104,622
U01 · FY2000 · AI
PHASE II ROLLING ARM MASTER PROTOCOL OF NOVEL ANTIRETROVIRAL THERAPY IN HIV$25,799
M01 · FY2000 · RR
CLINICAL INVESTIGATION OF THE PATIENT WITH PRIMARY IMMUNODEFICIENCY DISORDER$25,799
M01 · FY2000 · RR
PHASE I/II TRIAL OF RECOMBINANT IL 2 IN SYMPTOMATIC HIV INFECTED CHILDREN$25,799
M01 · FY2000 · RR
ATOVAQUONE IN HIV INFECTED INFANTS AND CHILDREN$25,799
M01 · FY2000 · RR
PEDIATRIC HIV LATE OUTCOMES PROTOCOL$25,799
M01 · FY2000 · RR
IMPACT OF DIAGNOSTIC DISCLOSURE ON HIV INFECTED CHILDREN$25,799
M01 · FY2000 · RR
NEVIRAPINE VS PLACEBO TO PREVENT MATERNAL-FETAL HIV TRANSMISSION$25,799
M01 · FY2000 · RR
PHASE I EVALUATION OF SAFETY/TOXICITY OF ZDV AND DDI COMBINATION THERAPY$25,799
M01 · FY2000 · RR
ATOVAQUONE AND AZT VERSUS TMP IN HIV INFECTED CHILDREN$25,799
M01 · FY2000 · RR
TREATING SCID DUE TO ADA DEFICIENCY WITH CD34+ SELECTED AUTOLOGOUS STEM CELLS$25,799
M01 · FY2000 · RR
ACTG 377: PRAM 2 COMPARING 4 ANTIRETROVIRAL REGIMENS$17,457
M01 · FY2000 · RR
ACTG 395: INDINAVIR W/ STAVUDINE &LAMIVUDINE FOR PEDIATRIC HIV 1 INF$17,457
M01 · FY2000 · RR
QUANTIFYING HIV 1 RNA IN CSF &BLOOD OF HIV INFECTED CHILDREN$17,457
M01 · FY2000 · RR
ACTG 351: CD4 IGG2 IN HIV INFECTED CHILDREN$17,457
M01 · FY2000 · RR
ACTG 366: ANTIRETROVIRAL ALGORITHM FOR CHILDREN OF 4 DRUG COMBINATION$17,457
M01 · FY2000 · RR
ACTG 316: NEVIRAPINE VS PLACEBO FOR PREVENTING MATERNAL FETAL TRANSMISSION$564
M01 · FY2000 · RR
ACTG 351: CD4 IGG2 IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
ACTG 351: CD4 IGG2 IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
NEVIRAPINE VS PLACEBO TO PREVENT MATERNAL-FETAL HIV TRANSMISSION$0
M01 · FY2000 · RR
NEVIRAPINE VS PLACEBO TO PREVENT MATERNAL-FETAL HIV TRANSMISSION$0
M01 · FY2000 · RR
PHASE II ROLLING ARM MASTER PROTOCOL OF NOVEL ANTIRETROVIRAL THERAPY IN HIV$0
M01 · FY2000 · RR
PHASE II ROLLING ARM MASTER PROTOCOL OF NOVEL ANTIRETROVIRAL THERAPY IN HIV$0
M01 · FY2000 · RR
PHASE I/II TRIAL OF RECOMBINANT IL 2 IN SYMPTOMATIC HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
PHASE I/II TRIAL OF RECOMBINANT IL 2 IN SYMPTOMATIC HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
IMPACT OF DIAGNOSTIC DISCLOSURE ON HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
IMPACT OF DIAGNOSTIC DISCLOSURE ON HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
PHASE I EVALUATION OF SAFETY/TOXICITY OF ZDV AND DDI COMBINATION THERAPY$0
M01 · FY2000 · RR
PHASE I EVALUATION OF SAFETY/TOXICITY OF ZDV AND DDI COMBINATION THERAPY$0
M01 · FY2000 · RR
PEDIATRIC HIV LATE OUTCOMES PROTOCOL$0
M01 · FY2000 · RR
SAQUINAVIR COMBINATION THERAPY FOR HIV CHILDREN$0
M01 · FY2000 · RR
SAQUINAVIR COMBINATION THERAPY FOR HIV CHILDREN$0
M01 · FY2000 · RR
CORRELATION OF GROWTH WITH HIV VIRAL LOAD IN CHILDREN$0
M01 · FY2000 · RR
CORRELATION OF GROWTH WITH HIV VIRAL LOAD IN CHILDREN$0
M01 · FY2000 · RR
CORRELATION OF GROWTH WITH HIV VIRAL LOAD IN CHILDREN$0
M01 · FY2000 · RR
OPPORTUNISTIC INFECTION EVENTS IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
OPPORTUNISTIC INFECTION EVENTS IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
TREATING SCID DUE TO ADA DEFICIENCY WITH CD34+ SELECTED AUTOLOGOUS STEM CELLS$0
M01 · FY2000 · RR
PEDIATRIC HIV LATE OUTCOMES PROTOCOL$0
M01 · FY2000 · RR
ATOVAQUONE AND AZT VERSUS TMP IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
ATOVAQUONE AND AZT VERSUS TMP IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
OPPORTUNISTIC INFECTION EVENTS IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
TREATING SCID DUE TO ADA DEFICIENCY WITH CD34+ SELECTED AUTOLOGOUS STEM CELLS$0
M01 · FY2000 · RR
ATOVAQUONE IN HIV INFECTED INFANTS AND CHILDREN$0
M01 · FY2000 · RR
ATOVAQUONE IN HIV INFECTED INFANTS AND CHILDREN$0
M01 · FY2000 · RR
CLINICAL INVESTIGATION OF THE PATIENT WITH PRIMARY IMMUNODEFICIENCY DISORDER$0
M01 · FY2000 · RR
CLINICAL INVESTIGATION OF THE PATIENT WITH PRIMARY IMMUNODEFICIENCY DISORDER$0
M01 · FY2000 · RR
ACTG 316: NEVIRAPINE VS PLACEBO FOR PREVENTING MATERNAL FETAL TRANSMISSION$0
M01 · FY2000 · RR
ACTG 316: NEVIRAPINE VS PLACEBO FOR PREVENTING MATERNAL FETAL TRANSMISSION$0
M01 · FY2000 · RR
SAQUINAVIR COMBINATION THERAPY FOR HIV CHILDREN$0
M01 · FY2000 · RR
ACTG 395: INDINAVIR W/ STAVUDINE &LAMIVUDINE FOR PEDIATRIC HIV 1 INF$0
M01 · FY2000 · RR
ACTG 395: INDINAVIR W/ STAVUDINE &LAMIVUDINE FOR PEDIATRIC HIV 1 INF$0
M01 · FY2000 · RR
ACTG 366: ANTIRETROVIRAL ALGORITHM FOR CHILDREN OF 4 DRUG COMBINATION$0
M01 · FY2000 · RR
ACTG 366: ANTIRETROVIRAL ALGORITHM FOR CHILDREN OF 4 DRUG COMBINATION$0
M01 · FY2000 · RR
ACTG 377: PRAM 2 COMPARING 4 ANTIRETROVIRAL REGIMENS$0
M01 · FY2000 · RR
ACTG 377: PRAM 2 COMPARING 4 ANTIRETROVIRAL REGIMENS$0
M01 · FY2000 · RR
QUANTIFYING HIV 1 RNA IN CSF &BLOOD OF HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
QUANTIFYING HIV 1 RNA IN CSF &BLOOD OF HIV INFECTED CHILDREN$0
M01 · FY2000 · RR